Illumina’s $7.1 Billion Grail Deal: Proxy Fight and Insurance Controversy with Carl Icahn

Illumina insurance deal

Illumina, a San Diego-based biotech firm, has recently acquired Grail, a cancer test developer, for a value of $7.1 billion, marking one of the biggest deals in the biotech industry. The acquisition has garnered significant criticism, primarily from activist investor Carl Icahn, who has pushed for board seats at Illumina. He alleges that the board required the company to commit to providing them with additional personal liability insurance protection one day before the Grail deal … Read more